Cargando…
First-line Treatment With Bendamustine and Rituximab for Old and Frail Patients With Aggressive Lymphoma: Results of the B-R-ENDA Trial
The incidence of aggressive B-cell lymphomas increases with age, but for elderly or frail patients not eligible for doxorubicin-containing treatment standard therapy remains to be defined. In this prospective, multicenter, phase-2 B-R-ENDA trial, we investigated the feasibility, toxicity, and effica...
Autores principales: | , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9722574/ https://www.ncbi.nlm.nih.gov/pubmed/36479544 http://dx.doi.org/10.1097/HS9.0000000000000808 |
_version_ | 1784843992567906304 |
---|---|
author | Braulke, Friederike Zettl, Florian Ziepert, Marita Viardot, Andreas Kahl, Christoph Prange-Krex, Gabriele Korfel, Agnieszka Dreyling, Martin Bott, Alexander Wedding, Ulrich Reichert, Dietmar de Wit, Maike Hartmann, Frank Poeschel, Viola Schmitz, Norbert Witzens-Harig, Mathias Klapper, Wolfram Rosenwald, Andreas Wulf, Gerald Altmann, Bettina Trümper, Lorenz |
author_facet | Braulke, Friederike Zettl, Florian Ziepert, Marita Viardot, Andreas Kahl, Christoph Prange-Krex, Gabriele Korfel, Agnieszka Dreyling, Martin Bott, Alexander Wedding, Ulrich Reichert, Dietmar de Wit, Maike Hartmann, Frank Poeschel, Viola Schmitz, Norbert Witzens-Harig, Mathias Klapper, Wolfram Rosenwald, Andreas Wulf, Gerald Altmann, Bettina Trümper, Lorenz |
author_sort | Braulke, Friederike |
collection | PubMed |
description | The incidence of aggressive B-cell lymphomas increases with age, but for elderly or frail patients not eligible for doxorubicin-containing treatment standard therapy remains to be defined. In this prospective, multicenter, phase-2 B-R-ENDA trial, we investigated the feasibility, toxicity, and efficacy of 8 cycles rituximab combined with 6 cycles bendamustine (BR) in elderly or frail aggressive B-cell lymphoma patients: 39 patients aged >80 years and 29 patients aged 61–80 years with elevated Cumulative Illness Rating Scalescore >6 were included. Progression-free survival (PFS) and overall survival (OS) at 2 years were 45% (95% confidence interval [CI], 28%-61%) and 46% (28%-63%) for the patients age >80, as well 32% (13%-51%) and 37% (17%-57%) for frail patients age 64–80, respectively. In a preplanned retrospective analysis, we found no significant differences in PFS and OS comparing the outcome of the 39 patients age >80 years with 40 patients aged 76–80 years treated with 6xR-CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) and 2 x rituximab in the RICOVER-60 trial (DSHNHL 1999-1, NCT00052936, EU-20243), yet we detected lower rates of infections and treatment-related deaths in the BR-treated patients. We demonstrate that older and frail patients with aggressive B-cell lymphoma who are not able to receive standard CHOP-based therapy can benefit from anthracycline-free therapy as a feasible and effective therapeutic option. |
format | Online Article Text |
id | pubmed-9722574 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-97225742022-12-06 First-line Treatment With Bendamustine and Rituximab for Old and Frail Patients With Aggressive Lymphoma: Results of the B-R-ENDA Trial Braulke, Friederike Zettl, Florian Ziepert, Marita Viardot, Andreas Kahl, Christoph Prange-Krex, Gabriele Korfel, Agnieszka Dreyling, Martin Bott, Alexander Wedding, Ulrich Reichert, Dietmar de Wit, Maike Hartmann, Frank Poeschel, Viola Schmitz, Norbert Witzens-Harig, Mathias Klapper, Wolfram Rosenwald, Andreas Wulf, Gerald Altmann, Bettina Trümper, Lorenz Hemasphere Article The incidence of aggressive B-cell lymphomas increases with age, but for elderly or frail patients not eligible for doxorubicin-containing treatment standard therapy remains to be defined. In this prospective, multicenter, phase-2 B-R-ENDA trial, we investigated the feasibility, toxicity, and efficacy of 8 cycles rituximab combined with 6 cycles bendamustine (BR) in elderly or frail aggressive B-cell lymphoma patients: 39 patients aged >80 years and 29 patients aged 61–80 years with elevated Cumulative Illness Rating Scalescore >6 were included. Progression-free survival (PFS) and overall survival (OS) at 2 years were 45% (95% confidence interval [CI], 28%-61%) and 46% (28%-63%) for the patients age >80, as well 32% (13%-51%) and 37% (17%-57%) for frail patients age 64–80, respectively. In a preplanned retrospective analysis, we found no significant differences in PFS and OS comparing the outcome of the 39 patients age >80 years with 40 patients aged 76–80 years treated with 6xR-CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) and 2 x rituximab in the RICOVER-60 trial (DSHNHL 1999-1, NCT00052936, EU-20243), yet we detected lower rates of infections and treatment-related deaths in the BR-treated patients. We demonstrate that older and frail patients with aggressive B-cell lymphoma who are not able to receive standard CHOP-based therapy can benefit from anthracycline-free therapy as a feasible and effective therapeutic option. Lippincott Williams & Wilkins 2022-12-01 /pmc/articles/PMC9722574/ /pubmed/36479544 http://dx.doi.org/10.1097/HS9.0000000000000808 Text en Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY) (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Article Braulke, Friederike Zettl, Florian Ziepert, Marita Viardot, Andreas Kahl, Christoph Prange-Krex, Gabriele Korfel, Agnieszka Dreyling, Martin Bott, Alexander Wedding, Ulrich Reichert, Dietmar de Wit, Maike Hartmann, Frank Poeschel, Viola Schmitz, Norbert Witzens-Harig, Mathias Klapper, Wolfram Rosenwald, Andreas Wulf, Gerald Altmann, Bettina Trümper, Lorenz First-line Treatment With Bendamustine and Rituximab for Old and Frail Patients With Aggressive Lymphoma: Results of the B-R-ENDA Trial |
title | First-line Treatment With Bendamustine and Rituximab for Old and Frail Patients With Aggressive Lymphoma: Results of the B-R-ENDA Trial |
title_full | First-line Treatment With Bendamustine and Rituximab for Old and Frail Patients With Aggressive Lymphoma: Results of the B-R-ENDA Trial |
title_fullStr | First-line Treatment With Bendamustine and Rituximab for Old and Frail Patients With Aggressive Lymphoma: Results of the B-R-ENDA Trial |
title_full_unstemmed | First-line Treatment With Bendamustine and Rituximab for Old and Frail Patients With Aggressive Lymphoma: Results of the B-R-ENDA Trial |
title_short | First-line Treatment With Bendamustine and Rituximab for Old and Frail Patients With Aggressive Lymphoma: Results of the B-R-ENDA Trial |
title_sort | first-line treatment with bendamustine and rituximab for old and frail patients with aggressive lymphoma: results of the b-r-enda trial |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9722574/ https://www.ncbi.nlm.nih.gov/pubmed/36479544 http://dx.doi.org/10.1097/HS9.0000000000000808 |
work_keys_str_mv | AT braulkefriederike firstlinetreatmentwithbendamustineandrituximabforoldandfrailpatientswithaggressivelymphomaresultsofthebrendatrial AT zettlflorian firstlinetreatmentwithbendamustineandrituximabforoldandfrailpatientswithaggressivelymphomaresultsofthebrendatrial AT ziepertmarita firstlinetreatmentwithbendamustineandrituximabforoldandfrailpatientswithaggressivelymphomaresultsofthebrendatrial AT viardotandreas firstlinetreatmentwithbendamustineandrituximabforoldandfrailpatientswithaggressivelymphomaresultsofthebrendatrial AT kahlchristoph firstlinetreatmentwithbendamustineandrituximabforoldandfrailpatientswithaggressivelymphomaresultsofthebrendatrial AT prangekrexgabriele firstlinetreatmentwithbendamustineandrituximabforoldandfrailpatientswithaggressivelymphomaresultsofthebrendatrial AT korfelagnieszka firstlinetreatmentwithbendamustineandrituximabforoldandfrailpatientswithaggressivelymphomaresultsofthebrendatrial AT dreylingmartin firstlinetreatmentwithbendamustineandrituximabforoldandfrailpatientswithaggressivelymphomaresultsofthebrendatrial AT bottalexander firstlinetreatmentwithbendamustineandrituximabforoldandfrailpatientswithaggressivelymphomaresultsofthebrendatrial AT weddingulrich firstlinetreatmentwithbendamustineandrituximabforoldandfrailpatientswithaggressivelymphomaresultsofthebrendatrial AT reichertdietmar firstlinetreatmentwithbendamustineandrituximabforoldandfrailpatientswithaggressivelymphomaresultsofthebrendatrial AT dewitmaike firstlinetreatmentwithbendamustineandrituximabforoldandfrailpatientswithaggressivelymphomaresultsofthebrendatrial AT hartmannfrank firstlinetreatmentwithbendamustineandrituximabforoldandfrailpatientswithaggressivelymphomaresultsofthebrendatrial AT poeschelviola firstlinetreatmentwithbendamustineandrituximabforoldandfrailpatientswithaggressivelymphomaresultsofthebrendatrial AT schmitznorbert firstlinetreatmentwithbendamustineandrituximabforoldandfrailpatientswithaggressivelymphomaresultsofthebrendatrial AT witzensharigmathias firstlinetreatmentwithbendamustineandrituximabforoldandfrailpatientswithaggressivelymphomaresultsofthebrendatrial AT klapperwolfram firstlinetreatmentwithbendamustineandrituximabforoldandfrailpatientswithaggressivelymphomaresultsofthebrendatrial AT rosenwaldandreas firstlinetreatmentwithbendamustineandrituximabforoldandfrailpatientswithaggressivelymphomaresultsofthebrendatrial AT wulfgerald firstlinetreatmentwithbendamustineandrituximabforoldandfrailpatientswithaggressivelymphomaresultsofthebrendatrial AT altmannbettina firstlinetreatmentwithbendamustineandrituximabforoldandfrailpatientswithaggressivelymphomaresultsofthebrendatrial AT trumperlorenz firstlinetreatmentwithbendamustineandrituximabforoldandfrailpatientswithaggressivelymphomaresultsofthebrendatrial |